

# Teva 2017 Social Impact Report Highlights

## Contributing to healthy communities

### Announced Social Impact Signature Initiative to address non-communicable diseases (NCDs):



Partnered with **Mount Sinai** on scalable program to address needs of patients with multiple chronic conditions (MCC)



Provided **\$300,000** to four clinics across the U.S. to support patients with MCC via two-year Enhancing Access2Care grant program with Direct Relief and Volunteers in Medicine



Published **independent report** quantifying MCC challenges



Launched **AUSTEDO®** (deutetrabenazine),<sup>1</sup> the first and only FDA-approved product to treat both tardive dyskinesia in adults and chorea associated with Huntington's disease disorders that cause involuntary movements



Invested more than **\$1.8B in research and development**



Won **2 grants** from the European Research Network to:  
(1) research Huntington's disease  
(2) develop nanotechnology tools for drug delivery



Launched **5 new medicines to prevent and treat** human immunodeficiency virus (HIV)



Launched a **generic version of AirDuo RespiClick®** for asthma patients in the U.S., at a price significantly lower than the originator version



Supplied **3.02 million tablets** of Linezolid for multidrug-resistant tuberculosis, saving **\$2,000+ per patient per year**



Donated **\$82.3M** and supported communities across more than **25 countries**



Supported **80 patient educational programs** in **38 countries**, reaching more than **300,000 patients**

1. Teva. (2017). AUSTEDO® prescribing information. Available <https://www.austedo.com/hd/pi> (accessed July 2018)

All dollar amounts listed are USD

# Teva 2017 Social Impact Report Highlights

## Leading a responsible business



Developed **6 new corporate positions and policies**, establishing our commitment to donations, human rights, diversity and inclusion, occupational health and safety, the environment, and antimicrobial resistance (AMR)



Invested **\$120M in global programs** to make medicines at 38 facilities counterfeit-compliant ahead of anticipated regulatory change



Reduced water withdrawal **by 23%** at 3 water-scarce sites in Israel and India



Continuously improved occupational safety performance, with **7% reduction** in recordable injury rate and **23% reduction** in lost day rate



Recycled **40%** of waste



Conducted **93** leadership development workshops for **1,500 managers**



Implemented Code of Conduct training, reaching **99% of employees**



Achieved **30%** of global electricity supply from green (renewable) sources



Donated more than **36,000 products** to more than **20,000 patients** through Teva Cares Foundation



Achieved the lowest greenhouse gas emissions efficiency rate in Teva's history, **8% lower** than in 2016 and **24% lower** than in 2012